Key facts
- This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Mar 2024, 16:08.
Pascal Deschatelets - 08 Mar 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- APLS
- Reported as of
- 08 Mar 2024
- Net transaction value
- -$4,043,926
- SEC form
- 4
- Accepted by SEC
- 11 Mar 2024, 16:08:32 UTC
- Prior SEC filing
- 13 Feb 2024
- Next SEC filing
- 09 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 11 Mar 2024.
Change
- Previous filing in this sequence was filed on 13 Feb 2024.
- Current net transaction value: -$4,043,926.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Options Exercise
- Transaction value
- $253,623
- Shares
- +69,107
- Change %
- +6.2%
- Price
- $3.67*
- Shares after
- 1,185,090
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
APLS
transaction
Common Stock
Sale
- Transaction value
- $2,645,173
- Shares
- -42,750
- Change %
- -3.6%
- Price
- $61.88
- Shares after
- 1,142,340
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F2, F3
APLS
transaction
Common Stock
Sale
- Transaction value
- $1,646,041
- Shares
- -26,257
- Change %
- -2.3%
- Price
- $62.69
- Shares after
- 1,116,083
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F4, F5
APLS
transaction
Common Stock
Sale
- Transaction value
- $6,335
- Shares
- -100
- Change %
- -0.01%
- Price
- $63.35
- Shares after
- 1,115,983
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -69,107
- Change %
- -39%
- Price
- $0.000000
- Shares after
- 106,387
- Date
- 08 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,107
- Exercise price
- $3.76
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
Footnote F2
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $61.30 - $62.295. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F4
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
Footnote F5
This transaction was executed in multiple trades at prices ranging from $62.30 - $63.2925. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F6
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
Footnote F7
This stock option was granted on 02/08/2016 and is fully vested.